Additional Details
-
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Kelowna Allergy and Respiratory Health ClinicKelowna BC. V1W 1V3 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of Kansas Medical CenterKansas City KS. 66160 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of Alabama at BirminghamBirmingham AL. 35294-3300 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Dynamic Drug Advancement Ltd.Ajax ON. L1S 2J5 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
University of California, San Francisco Medical CenterSan Francisco CA. 94115 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
IU Health Ball Memorial Physicians Pulmonary and Critical Care MedicineMuncie IN. 47303-3432 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Central Florida Pulmonary Group, PAOrlando FL. 32803 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Southeastern Research CenterWinston-Salem NC. 27103-4029 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Hannibal Regional Healthcare System HRMG HannibalHannibal MO. 63401-6890 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Pulmonix LLCGreensboro NC. 27403 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Coastal Pulmonary and Critical Care PLCSaint Petersburg FL. 33704-2733 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Renstar Medical ResearchOcala FL. 34470 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
El Paso Pulmonary Association Elligo PPDSEl Paso TX. 79902-1124 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Temple UniversityPhiladelphia PA. 19140 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of Iowa Hospitals and ClinicsIowa City IA. 52242 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of Texas Health Science Center at Houston (UT Health)Houston TX. 77030 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Northwestern UniversityEvanston IL. 60208 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Penn State Health Milton S. Hershey Medical CenterHershey PA. 17033 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of California Irvine (UCI) HealthOrange CA. 92868 -
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
University of FloridaGainesville FL. 32608